drugset
drugset / Trial / NCT00687505

Safety Study of FP-1039 To Treat Cancer

NCT00687505 ↗

Phase 1 Completed 39 enrolled Five Prime Therapeutics, Inc. Parexel · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the safety and tolerability of FP-1039, a new biologic treatment for cancer.

Timeline

Start
2008-07
Primary completion
2011-05
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject FP-1039 Unknown — Intravenous

Indications

No indication recorded.